Overactive Bladder – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Overactive Bladder – Pipeline Review, H2 2017’, provides an overview of the Overactive Bladder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Overactive Bladder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Overactive Bladder

The report reviews pipeline therapeutics for Overactive Bladder by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Overactive Bladder therapeutics and enlists all their major and minor projects

The report assesses Overactive Bladder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Overactive Bladder

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Overactive Bladder

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Allergan Plc

Asahi Kasei Pharma Corp

Astellas Pharma Inc

Dompe Farmaceutici SpA

Dong-A ST Co Ltd

FemmePharma Global Healthcare Inc

Hanmi Pharmaceuticals Co Ltd

Hydra Biosciences Inc

Ion Channel Innovations LLC

Ipsen SA

Juniper Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Lipella Pharmaceuticals Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

Ono Pharmaceutical Co Ltd

Recordati SpA

Taiho Pharmaceutical Co Ltd

Taris Biomedical LLC

TheraVida Inc

Toray Industries Inc

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 6

Global Markets Direct Report Coverage 6

Overactive Bladder - Overview 7

Overactive Bladder - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 15

Overactive Bladder - Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Overactive Bladder - Companies Involved in Therapeutics Development 24

Addex Therapeutics Ltd 24

Allergan Plc 24

Asahi Kasei Pharma Corp 25

Astellas Pharma Inc 25

Dompe Farmaceutici SpA 26

Dong-A ST Co Ltd 26

FemmePharma Global Healthcare Inc 26

Hanmi Pharmaceuticals Co Ltd 27

Hydra Biosciences Inc 27

Ion Channel Innovations LLC 28

Ipsen SA 28

Juniper Pharmaceuticals Inc 28

Kissei Pharmaceutical Co Ltd 29

Kyorin Pharmaceutical Co Ltd 29

Lipella Pharmaceuticals Inc 30

Merck & Co Inc 30

Mezzion Pharma Co Ltd 31

Ono Pharmaceutical Co Ltd 31

Recordati SpA 32

Taiho Pharmaceutical Co Ltd 32

Taris Biomedical LLC 32

TheraVida Inc 33

Toray Industries Inc 33

XuanZhu Pharma Co Ltd 34

Overactive Bladder - Drug Profiles 35

(mirabegron + solifenacin succinate) - Drug Profile 35

abobotulinumtoxinA - Drug Profile 37

ADX-71441 - Drug Profile 41

AK-14 - Drug Profile 46

DA-8010 - Drug Profile 47

DFL-23448 - Drug Profile 48

fadanafil - Drug Profile 49

fesoterodine - Drug Profile 50

HC-067047 - Drug Profile 51

ICE-3682 - Drug Profile 52

KPR-2579 - Drug Profile 53

mirabegron ER - Drug Profile 54

onabotulinumtoxinA - Drug Profile 58

onabotulinumtoxinA - Drug Profile 63

onabotulinumtoxinA SR - Drug Profile 65

ONO-8577 - Drug Profile 66

oxybutynin chloride - Drug Profile 67

oxybutynin chloride - Drug Profile 68

Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder - Drug Profile 69

pVAX-hSlo - Drug Profile 70

REC-0438 - Drug Profile 72

Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile 73

Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile 74

Small Molecules to Antagonize PTGER1 for Overactive Bladder - Drug Profile 75

solabegron hydrochloride - Drug Profile 76

solabegron hydrochloride MR - Drug Profile 79

solifenacin succinate - Drug Profile 80

solifenacin succinate - Drug Profile 82

TAC-302 - Drug Profile 83

THVD-201 - Drug Profile 84

trospium chloride - Drug Profile 86

udenafil - Drug Profile 87

vibegron - Drug Profile 91

Overactive Bladder - Dormant Projects 93

Overactive Bladder - Discontinued Products 97

Overactive Bladder - Product Development Milestones 98

Featured News & Press Releases 98

Appendix 107

Methodology 107

Coverage 107

Secondary Research 107

Primary Research 107

Expert Panel Validation 107

Contact Us 107

Disclaimer 108

List of Tables

List of Tables

Number of Products under Development for Overactive Bladder, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Overactive Bladder – Pipeline by Addex Therapeutics Ltd, H2 2017

Overactive Bladder – Pipeline by Allergan Plc, H2 2017

Overactive Bladder – Pipeline by Asahi Kasei Pharma Corp, H2 2017

Overactive Bladder – Pipeline by Astellas Pharma Inc, H2 2017

Overactive Bladder – Pipeline by Dompe Farmaceutici SpA, H2 2017

Overactive Bladder – Pipeline by Dong-A ST Co Ltd, H2 2017

Overactive Bladder – Pipeline by FemmePharma Global Healthcare Inc, H2 2017

Overactive Bladder – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Overactive Bladder – Pipeline by Hydra Biosciences Inc, H2 2017

Overactive Bladder – Pipeline by Ion Channel Innovations LLC, H2 2017

Overactive Bladder – Pipeline by Ipsen SA, H2 2017

Overactive Bladder – Pipeline by Juniper Pharmaceuticals Inc, H2 2017

Overactive Bladder – Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017

Overactive Bladder – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017

Overactive Bladder – Pipeline by Lipella Pharmaceuticals Inc, H2 2017

Overactive Bladder – Pipeline by Merck & Co Inc, H2 2017

Overactive Bladder – Pipeline by Mezzion Pharma Co Ltd, H2 2017

Overactive Bladder – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Overactive Bladder – Pipeline by Recordati SpA, H2 2017

Overactive Bladder – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017

Overactive Bladder – Pipeline by Taris Biomedical LLC, H2 2017

Overactive Bladder – Pipeline by TheraVida Inc, H2 2017

Overactive Bladder – Pipeline by Toray Industries Inc, H2 2017

Overactive Bladder – Pipeline by XuanZhu Pharma Co Ltd, H2 2017

Overactive Bladder – Dormant Projects, H2 2017

Overactive Bladder – Dormant Projects, H2 2017 (Contd..1), H2 2017

Overactive Bladder – Dormant Projects, H2 2017 (Contd..2), H2 2017

Overactive Bladder – Dormant Projects, H2 2017 (Contd..3), H2 2017

Overactive Bladder – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Overactive Bladder, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports